Psychedelic Clinical Trials
Find clinical trials studying psilocybin, MDMA, ketamine and other psychedelics. Many trials are actively recruiting participants who haven't found relief from conventional treatments.
Trifecta Research Study
Axial Therapeutic Research
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Portland VA Research Foundation, Inc
Comparing the Effects of Psilocin and Psilocybin in Healthy Adults
University of California, San Francisco
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
Ohio State University
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Novartis Pharmaceuticals
Ketamine and Kidney Injury in Cardiac Surgery
Mayo Clinic
Covid-19 Vaccine Immune Response in Multiple Sclerosis
University Hospitals of North Midlands NHS Trust
Psilocybin Therapy for Depression in Bipolar II Disorder
University of California, San Francisco
Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain
NYU Langone Health
Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure
Stanford University
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Biogen
Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin
King's College London
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
Johns Hopkins University
Ketamine vs Lidocaine in Traumatic Rib Fractures
Brittany Hoyte
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Yale University
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
Bristol-Myers Squibb
Ketamine + Cognitive Training for Suicidality in the Medical Setting
Rebecca Price
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Sheppard Pratt Health System
Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder
Keith Heinzerling
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
New York State Psychiatric Institute
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
University Hospital, Geneva
Perioperative Lidocaine and Ketamine in Abdominal Surgery
The Cleveland Clinic
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
Rennes University Hospital
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
Mayo Clinic
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Yale University
Facilitating Rapid Naltrexone Initiation
New York State Psychiatric Institute
Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain
Jason McMullan
Understanding How Ketamine Brings About Rapid Improvement in OCD
Stanford University
Imaging SV2A in Mood Disorders
Yale University
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
Janssen Research & Development, LLC
BMN 110 US Expanded Access Program
BioMarin Pharmaceutical
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
Mayo Clinic
Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants
University Hospital, Basel, Switzerland
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
MycoMedica Life Sciences PBC
Drug Effects on Mood and Behavior - Expectancy
University of Chicago
Outcome of Multimodal Anesthesia Bern
Insel Gruppe AG, University Hospital Bern
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
The University of Texas Health Science Center at San Antonio
Mood Effects of Serotonin Agonists: Depression
University of Chicago
A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy
Novartis Pharmaceuticals
ESKetamine Low-dose vs Ketamine Low-dose for Severe Acute Pain in Emergency Units, Comparison of PsychodyslEptic Effects
Centre Hospitalier Universitaire de Nice
Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19
University of Texas at Austin
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
University Hospital, Basel, Switzerland
A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse
Novartis Pharmaceuticals
Dance Movement Therapy for Radio-oncological Patients
University of Erlangen-Nürnberg Medical School
Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants
University Hospital, Basel, Switzerland
Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures
Centre Hospitalier Universitaire de Nīmes
KF2024#1-trial: Esketamine Interaction Study
Helsinki University Central Hospital
A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
University of Washington
Browse by Condition
View all conditions →How to Join a Clinical Trial
Clinical trials are research studies that test new treatments. Participating can give you access to cutting-edge therapies while contributing to medical science. Each trial has specific eligibility criteria based on the research goals.
1. Review
Read the trial details, eligibility criteria, and what participation involves.
2. Contact
Reach out to the study team using the contact information provided.
3. Screen
Complete the screening process to determine if you're eligible.